Clinical and economic impact of a pharmacistmanaged i.v.-to-p.o. conversion service for levofloxacin in Taiwan

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 2, 2012, Pages 136-141

  Yen, Yu Hsuan ^a,b   Chen, Hsiang Yin ^a,b   Leu, Wuan Jin ^b,c   Lin, You Meei ^b,c   Shen, Wan C ^a,b   Cheng, Kuei Ju ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antibiotics convertion; Levofloxacin; Pharmacist intervention

Indexed keywords

LEVOFLOXACIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CONVERSION SERVICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HOSPITALIZATION; HUMAN; INTERVENTION STUDY; LENGTH OF STAY; MALE; PERSONNEL MANAGEMENT; PHARMACIST; PREINTEREVENTION PERIOD; PROACTIVE CONVERSION PERIOD; REIMBURSEMENT; RETROSPECTIVE STUDY; TAIWAN; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; OFLOXACIN; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 84862912918     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201579     Document Type: Article

References (17)

1. Hindler J. Current status of antimicrobial resistance in Gram-positive bacteria in Taiwan NHRI Communications 2009; p. 287.
2. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44: 159-177. doi:10.1086/510393 PubMed (Pubitemid 46084814)
3. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. Am J Health Syst Pharm. 2002; 59: 2209-2215. PubMed (Pubitemid 35315724)
4. Pablos AI, Escobar I, Albiñana S, Serrano O, Ferrari JM, Herreros de Tejada A. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Saf. 2005; 14: 53-59. PubMed doi:10.1002/pds.1042
5. NHI, Insurance NH. Reimbursements Taipei: Bureau of National Health Insurance.
6. Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001; 33: 289-295. doi:10.1086/321880 PubMed (Pubitemid 32664829)
7. WHO, Guidelines for ATC classification and DDD assignment 2011. WHO Collaborating Centre for Drug Statistics Methodology, 2011. p. 34.
8. Ho BP, Lau TT, Balen RM, Naumann TL, Jewesson PJ. The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: a pre- and post-intervention study. BMC Health Serv Res. 2005; 5: 48. doi:10.1186/1472-6963-5-48 PubMed
9. Buyle F, Vogelaers D, Peleman R, Van Maele G, Robays H. Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital. Pharm World Sci. 2010; 32: 404-410. doi:10.1007/s11096-010-9384-y PubMed
10. Banko HP. MSHG, Pharm D, BCPS, FASHP, Erin Adams, Pharm D. Smoothing the path for intravenous (IV) to Oral (PO) conversion: Where have we come in 11 years? Hosp Pharm. 2009; 44: 25-56. doi:10.1310/hpj4411-959
11. Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs. 2008; 68: 2469-2481. doi:10.2165/0003495-200868170-00005 PubMed
12. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006; 90: 1197-1222. doi:10.1016/j.mcna.2006.07.009 PubMed (Pubitemid 44751032)
13. Davis SL, Delgado G Jr, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis. 2005; 41 (Suppl 2): S136-S143. doi:10.108 6/428054 PubMed
14. Kuper KM. Intravenous to oral therapy conversion: ASHP; 2008.
15. Clarkson AWV, Hills T. Guideline for the intravenous to oral switch of antibiotic therapy. NHS Trust 2010.
16. Fox ERBM, Tyler LS. Pharmcy-administered iv to oral therapeutic interchange program: development, implementation, and cost-assessment. Hosp Pharm. 2003; 38: 444-452.
17. McLaughlin CM, Bodasing N, Boyter AC, Fenelon C, Fox JG, Seaton RA. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: an intervention study. QJM. 2005; 98: 745-752. doi:10.1093/qjmed/ hci114 PubMed (Pubitemid 41548552)